Dasatinib treatment of chronic myeloid leukemia markedly
A clinical study results, published in the 48th Annual Meeting of the American Society of Hematology (ASH) recently held Nepal resistant or intolerant chronic myeloid leukemia (CML) in chronic phase patients with imatinib updasatinib (dasatinib) treatment, can achieve hematologic and cytogenetic response, and the lasting effect.
This open, multi-center international clinical study, a group of patients taking dasatinib 70 mg per day, taken twice; another group of patients taking imatinib, the dose was increased to 800 mg per day (two efficacy and safety in patients with previous underwent daily 400 to 600 mg of imatinib). The data analysis shows that after 3 months of treatment and 15 months, the dasatinib-treated patients to achieve and maintain the number of patients with major cytogenetic response from 36% to 53%, higher than the imatinib group . The difference was statistically significant.
Dasatinib is the first FDA-approved oral multi-targeted kinase inhibitor can be combined with the BCR-ABL kinase multiple conformation for the treatment of the past (including the use of imatinib) treatment failure or intolerance various stages of adult patients with CML, including the chronic phase, accelerated phase, and myeloid cells or lymphocytes blastic phase.
Dasatinib treatment of chronic myeloid leukemia markedly
ReplyDeleteA clinical study results, published in the 48th Annual Meeting of the American Society of Hematology (ASH) recently held Nepal resistant or intolerant chronic myeloid leukemia (CML) in chronic phase patients with imatinib updasatinib (dasatinib) treatment, can achieve hematologic and cytogenetic response, and the lasting effect.
This open, multi-center international clinical study, a group of patients taking dasatinib 70 mg per day, taken twice; another group of patients taking imatinib, the dose was increased to 800 mg per day (two efficacy and safety in patients with previous underwent daily 400 to 600 mg of imatinib). The data analysis shows that after 3 months of treatment and 15 months, the dasatinib-treated patients to achieve and maintain the number of patients with major cytogenetic response from 36% to 53%, higher than the imatinib group . The difference was statistically significant.
Dasatinib is the first FDA-approved oral multi-targeted kinase inhibitor can be combined with the BCR-ABL kinase multiple conformation for the treatment of the past (including the use of imatinib) treatment failure or intolerance various stages of adult patients with CML, including the chronic phase, accelerated phase, and myeloid cells or lymphocytes blastic phase.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Tandutinib
KW-2449
Quizartinib
AST 487
Linifanib
Canertinib
Canertinib dihydrochloride
CP-724714 (E-Double bond)
2-Methoxyestradiol
GSK1904529A